Metastatic colorectal cancer-prolonging overall survival with targeted therapies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. MMP11 predicts colorectal cancer outcomes and its inhibitor RXP03 exerts anti-tumor effects via apoptosis activation.BMC gastroenterology · 2025
   Article
2. A Real-World Study of Safety, Immunogenicity and Efficacy of Bevacizumab in Patients With Solid Malignancies: A Phase IV, Post-Marketing Study in India.Cancer informatics · 2023
   Article
3. Long-Term Survivors of Metastatic Colorectal Cancer: A Tertiary Care Centre Experience.South Asian journal of cancer · 2021
   Article
4. New insights in the clinical implication of HOXA5 as prognostic biomarker in patients with colorectal cancer.Cancer biomarkers : section A of Disease markers · 2021
   Article
5. MiR-802 Suppresses Colorectal Cancer Cell Viability, Migration and Invasion by Targeting RAN.Cancer management and research · 2020
   Article
6. European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects.Virchows Archiv : an international journal of pathology · 2019
   Article
7. Inhibitory effects of petasin on human colon carcinoma cells mediated by inactivation of Akt/mTOR pathway.Chinese medical journal · 2019
   Article
8. Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.Journal of translational medicine · 2018
   Article
9. High expression of DJ-1 promotes growth and invasion via the PTEN-AKT pathway and predicts a poor prognosis in colorectal cancer.Cancer medicine · 2018
   Article
10. Technical Validation of a Reverse-Transcription Quantitative Polymerase Chain Reaction In Vitro Diagnostic Test for the Determination of MiR-31-3p Expression Levels in Formalin-Fixed Paraffin-Embedded Metastatic Colorectal Cancer Tumor Specimens.Biomarker insights · 2018
    Article
11. Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers-a Study from Indian Regional Cancer Centre.Indian journal of surgical oncology · 2017
    Article
12. miR-429 mediates tumor growth and metastasis in colorectal cancer.American journal of cancer research · 2017
    Article
13. Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer.Frontiers in genetics · 2015
    Article
14. Aberrant Expression of MicroRNA-15a and MicroRNA-16 Synergistically Associates with Tumor Progression and Prognosis in Patients with Colorectal Cancer.Gastroenterology research and practice · 2014
    Article
15. Upregulation of microRNA-196a and microRNA-196b cooperatively correlate with aggressive progression and unfavorable prognosis in patients with colorectal cancer.Cancer cell international · 2014
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as